[go: up one dir, main page]

HK1112862A1 - - Google Patents

Info

Publication number
HK1112862A1
HK1112862A1 HK08101831.3A HK08101831A HK1112862A1 HK 1112862 A1 HK1112862 A1 HK 1112862A1 HK 08101831 A HK08101831 A HK 08101831A HK 1112862 A1 HK1112862 A1 HK 1112862A1
Authority
HK
Hong Kong
Prior art keywords
amino
salt
cyanoethenyl
benzonitrile
dimethylphenyl
Prior art date
Application number
HK08101831.3A
Other languages
English (en)
Inventor
Paul Theodoor Agnes Stevens
Jozef Peeters
Roger Petrus Gerebern Vandecruys
Alfred Elisabeth Stappers
Alex Herman Copmans
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from MYPI20043578A external-priority patent/MY169670A/en
Priority claimed from PCT/EP2005/054341 external-priority patent/WO2006024667A1/fr
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1112862A1 publication Critical patent/HK1112862A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HK08101831.3A 2004-09-02 2008-02-20 HK1112862A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
MYPI20043578A MY169670A (en) 2003-09-03 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (fr) 2003-09-03 2004-09-03 Combinaisons d'une pyrimidine renfermant nnrti avec des inhibiteurs de rt
EP05101447 2005-02-25
PCT/EP2005/054341 WO2006024667A1 (fr) 2004-09-02 2005-09-02 Furamate de 4- ( (4- ( (4- (2-cyanoethenyl) -2, 6-dimethylphenyl) amino) -2-pyrimidinyl) amino) benzonitrile

Publications (1)

Publication Number Publication Date
HK1112862A1 true HK1112862A1 (fr) 2008-09-19

Family

ID=38091631

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08101831.3A HK1112862A1 (fr) 2004-09-02 2008-02-20

Country Status (15)

Country Link
US (3) US20090215804A1 (fr)
JP (1) JP4922937B2 (fr)
AT (1) ATE550074T1 (fr)
BR (1) BRPI0514861A (fr)
CR (1) CR9032A (fr)
DK (1) DK1789139T3 (fr)
EA (1) EA011036B1 (fr)
ES (1) ES2384715T3 (fr)
HK (1) HK1112862A1 (fr)
HR (1) HRP20120499T1 (fr)
IL (1) IL181649A0 (fr)
MX (1) MX2007002594A (fr)
NI (1) NI200700069A (fr)
NO (1) NO339788B1 (fr)
SI (1) SI1789139T1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126949B2 (en) 2011-04-25 2015-09-08 Hetero Research Foundation Process for rilpivirine
BR112022006296A2 (pt) * 2019-10-10 2022-06-28 Axcella Health Inc Formulações de volume reduzido incluindo entidades de aminoácidos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498419A (en) * 1994-06-03 1996-03-12 Pars; Harry G. Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
WO2004016581A1 (fr) * 2002-08-09 2004-02-26 Janssen Pharmaceutica N.V. Procedes de preparation de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
KR20110132482A (ko) * 2003-02-07 2011-12-07 얀센 파마슈티카 엔.브이. Ｈｉｖ 감염 예방용 피리미딘 유도체

Also Published As

Publication number Publication date
EA011036B1 (ru) 2008-12-30
ATE550074T1 (de) 2012-04-15
ES2384715T3 (es) 2012-07-11
JP4922937B2 (ja) 2012-04-25
NI200700069A (es) 2015-12-10
SI1789139T1 (sl) 2012-08-31
MX2007002594A (es) 2007-04-25
DK1789139T3 (da) 2012-07-09
CR9032A (es) 2009-07-30
EA200700534A1 (ru) 2007-08-31
NO339788B1 (no) 2017-01-30
US20090215804A1 (en) 2009-08-27
US20180116964A1 (en) 2018-05-03
IL181649A0 (en) 2007-07-04
US20110150996A1 (en) 2011-06-23
NO20071720L (no) 2007-04-02
JP2008511591A (ja) 2008-04-17
HRP20120499T1 (hr) 2012-07-31
BRPI0514861A (pt) 2008-06-24

Similar Documents

Publication Publication Date Title
FR16C1025I1 (fr) Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
HK1174922A1 (en) Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6- dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile 4-[[4-[[4-(2-)-2,6-]]-2-]]
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
AP1449A (en) Pharmaceutical compositions comprising a hmg reductase inhibitor.
RS20060260A (en) Method for the production of amino crotonyl compounds
WO2009007441A3 (fr) Forme cristalline de 4-[[4-[[4-(2-cyanoéthényl)-2,6-diméthylphényl]amino]-2-pyrimidinyl]amino]benzonitrile
PL1632232T6 (pl) Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
HK1112862A1 (fr)
UA92469C2 (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
HRP20110563T1 (en) Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile